525 related articles for article (PubMed ID: 25223574)
1. P2X7 receptor: an emerging target in central nervous system diseases.
Sperlágh B; Illes P
Trends Pharmacol Sci; 2014 Oct; 35(10):537-47. PubMed ID: 25223574
[TBL] [Abstract][Full Text] [Related]
2. P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases.
Illes P
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825423
[TBL] [Abstract][Full Text] [Related]
3. P2X7 receptors: channels, pores and more.
Volonté C; Apolloni S; Skaper SD; Burnstock G
CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):705-21. PubMed ID: 22963440
[TBL] [Abstract][Full Text] [Related]
4. The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases.
Calzaferri F; Ruiz-Ruiz C; de Diego AMG; de Pascual R; Méndez-López I; Cano-Abad MF; Maneu V; de Los Ríos C; Gandía L; García AG
Med Res Rev; 2020 Nov; 40(6):2427-2465. PubMed ID: 32677086
[TBL] [Abstract][Full Text] [Related]
5. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of P2X7 receptors in CNS health and disease.
Tewari M; Seth P
Ageing Res Rev; 2015 Nov; 24(Pt B):328-42. PubMed ID: 26478005
[TBL] [Abstract][Full Text] [Related]
7. P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders.
Chrovian CC; Rech JC; Bhattacharya A; Letavic MA
Prog Med Chem; 2014; 53():65-100. PubMed ID: 24418608
[TBL] [Abstract][Full Text] [Related]
8. P2X7 receptor antagonists: a patent review (2010-2015).
Park JH; Kim YC
Expert Opin Ther Pat; 2017 Mar; 27(3):257-267. PubMed ID: 27724045
[TBL] [Abstract][Full Text] [Related]
9. Involvement of microglial P2X7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses.
Chu YX; Zhang Y; Zhang YQ; Zhao ZQ
Brain Behav Immun; 2010 Oct; 24(7):1176-89. PubMed ID: 20554014
[TBL] [Abstract][Full Text] [Related]
10. The P2X7 receptor: A main player in inflammation.
Adinolfi E; Giuliani AL; De Marchi E; Pegoraro A; Orioli E; Di Virgilio F
Biochem Pharmacol; 2018 May; 151():234-244. PubMed ID: 29288626
[TBL] [Abstract][Full Text] [Related]
11. Purinergic Signalling and Neurological Diseases: An Update.
Burnstock G
CNS Neurol Disord Drug Targets; 2017; 16(3):257-265. PubMed ID: 27658510
[TBL] [Abstract][Full Text] [Related]
12. P2X7 receptors in the central nervous system.
Miras-Portugal MT; Ortega F; Gómez-Villafuertes R; Gualix J; Pérez-Sen R; Delicado EG
Biochem Pharmacol; 2021 May; 187():114472. PubMed ID: 33587917
[TBL] [Abstract][Full Text] [Related]
13. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease.
Bartlett R; Stokes L; Sluyter R
Pharmacol Rev; 2014 Jul; 66(3):638-75. PubMed ID: 24928329
[TBL] [Abstract][Full Text] [Related]
14. P2X7 receptor inhibition ameliorates dendritic spine pathology and social behavioral deficits in Rett syndrome mice.
Garré JM; Silva HM; Lafaille JJ; Yang G
Nat Commun; 2020 Apr; 11(1):1784. PubMed ID: 32286307
[TBL] [Abstract][Full Text] [Related]
15. The P2X7 purinergic receptor: An emerging therapeutic target in cardiovascular diseases.
Chen Z; He L; Li L; Chen L
Clin Chim Acta; 2018 Apr; 479():196-207. PubMed ID: 29366837
[TBL] [Abstract][Full Text] [Related]
16. A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists.
Soni S; Lukhey MS; Thawkar BS; Chintamaneni M; Kaur G; Joshi H; Ramniwas S; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4643-4656. PubMed ID: 38349395
[TBL] [Abstract][Full Text] [Related]
17. Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists.
El Idrissi IG; Podlewska S; Abate C; Bojarski AJ; Lacivita E; Leopoldo M
Curr Med Chem; 2024; 31(11):1361-1403. PubMed ID: 37013427
[TBL] [Abstract][Full Text] [Related]
18. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor.
Hempel C; Nörenberg W; Sobottka H; Urban N; Nicke A; Fischer W; Schaefer M
Neuropharmacology; 2013 Dec; 75():365-79. PubMed ID: 23954492
[TBL] [Abstract][Full Text] [Related]
19. A Possible Causal Involvement of Neuroinflammatory, Purinergic P2X7 Receptors in Psychiatric Disorders.
Zhang Y; Yin HY; Rubini P; Tang Y; Illes P
Curr Neuropharmacol; 2022; 20(11):2142-2155. PubMed ID: 35236262
[TBL] [Abstract][Full Text] [Related]
20. Regulation of P2X7 receptor expression and function in the brain.
Jimenez-Mateos EM; Smith J; Nicke A; Engel T
Brain Res Bull; 2019 Sep; 151():153-163. PubMed ID: 30593878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
